B
Bandaru S. Reddy
Researcher at Rutgers University
Publications - 277
Citations - 28225
Bandaru S. Reddy is an academic researcher from Rutgers University. The author has contributed to research in topics: Azoxymethane & Colorectal cancer. The author has an hindex of 97, co-authored 277 publications receiving 27634 citations. Previous affiliations of Bandaru S. Reddy include Pharmacia & Dana Corporation.
Papers
More filters
Journal Article
Modulation of Apoptosis by Sulindac, Curcumin, Phenylethyl-3-methylcaffeate, and 6-Phenylhexyl Isothiocyanate: Apoptotic Index as a Biomarker in Colon Cancer Chemoprevention and Promotion
TL;DR: Data show that chemopreventive properties of agents are correlated with the degree of apoptosis, and apoptosis seems to be a reliable biomarker for the evaluation of potential agents for cancer prevention.
Journal ArticleDOI
Dietary factors in human colorectal cancer.
TL;DR: It is believed that continuing scrutiny and precise assessment of the benefits and potential risks of nutrients in the treatment and prevention of colorectal cancer will prove significant to controlling this devastating disease.
Journal Article
Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids
TL;DR: Results indicate that the modulation of eicosanoid production via the influence on COX activity and the suppression of apoptosis may play a key role in HFML diet-induced colon tumorigenesis.
Journal ArticleDOI
Increased Susceptibility of Nrf2 Knockout Mice to Colitis-Associated Colorectal Cancer
Tin Oo Khor,Mou-Tuan Huang,Auemduan Prawan,Yue Liu,Xingpei Hao,Siwang Yu,William Cheung,Jefferson Y. Chan,Bandaru S. Reddy,Chung S. Yang,Ah-Ng Tony Kong +10 more
TL;DR: The findings show that Nrf2 plays a critical role in protecting against inflammation-associated colorectal cancer.
Journal ArticleDOI
Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis.
Jagveer Singh,Abraham Rivenson,Mamoru Tomita,Seiichi Shimamura,Norio Ishibashi,Bandaru S. Reddy +5 more
TL;DR: Data suggest that oral administration of probiotic B. longum exerts strong antitumor activity, as indicated by modulation of the intermediate biomarkers of colon cancer, and consequently reduced tumor outcome.